| Literature DB >> 28174096 |
Christine T O Nguyen1, Flora Hui2, Jason Charng2, Shajan Velaedan2, Anna K van Koeverden2, Jeremiah K H Lim2, Zheng He2, Vickie H Y Wong2, Algis J Vingrys2, Bang V Bui2, Magnus Ivarsson2.
Abstract
The retina is an easily accessible out-pouching of the central nervous system (CNS) and thus lends itself to being a biomarker of the brain. More specifically, the presence of neuronal, vascular and blood-neural barrier parallels in the eye and brain coupled with fast and inexpensive methods to quantify retinal changes make ocular biomarkers an attractive option. This includes its utility as a biomarker for a number of cerebrovascular diseases as well as a drug pharmacology and safety biomarker for the CNS. It is a rapidly emerging field, with some areas well established, such as stroke risk and multiple sclerosis, whereas others are still in development (Alzheimer's, Parkinson's, psychological disease and cortical diabetic dysfunction). The current applications and future potential of retinal biomarkers, including potential ways to improve their sensitivity and specificity are discussed. This review summarises the existing literature and provides a perspective on the strength of current retinal biomarkers and their future potential.Entities:
Keywords: Biomarker; Brain; Disease; Eye; Pharmacology; Retina
Mesh：
Substances：
Year: 2017 PMID： 28174096 DOI： 10.1016/j.pharmthera.2017.02.009
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310